Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe pharminent June 29, 2026
Regulatory Replimune gets early August decision date for twice-rejected melanoma drug pharminent June 26, 2026
Clinical Data Pfizer drug acquired in Seagen deal disappoints in lung cancer study pharminent June 23, 2026
Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026
Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
M&A / Deals GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year pharminent June 9, 2026
M&A / Deals J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B pharminent June 8, 2026
Pipeline Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? pharminent June 5, 2026
M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets pharminent June 4, 2026
Manufacturing Cellares and TScan to assess automated manufacturing of TSC-101 therapy pharminent June 4, 2026
Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
Clinical Data ASCO: Merck overshadowed by upstart biotechs but TROP2 plans begin to pay off pharminent June 2, 2026
Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026
Clinical Data ASCO: Summit reached with China lung data but new climb begins to prove global benefit pharminent June 1, 2026
Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026
Clinical Data Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers pharminent May 29, 2026
